ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2020
Rapid Polymyxin/Pseudomonas NP test for rapid detection of polymyxin susceptibility/resistance in Pseudomonas aeruginosa.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Review
- Two novel rapid colorimetric methods for determination of colistin susceptibility in Enterobacterales isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Challenges in the Detection of Polymyxin Resistance: From Today to the Future.Microorganisms · 2024Review
- Rapid ResaCeftazidime-AvibactamJournal of clinical microbiology · 2022Article
- Rapid high-resolution detection of colistin resistance in Gram-negative bacteria using flow cytometry: a comparison with broth microdilution, a commercial screening test and WGS.The Journal of antimicrobial chemotherapy · 2021Article
- Evaluation of Rapid PolymyxinJAC-antimicrobial resistance · 2021Article
- Rapid ResaImipenem/Acinetobacter NP Test for Detection of Carbapenem Susceptibility/Resistance in Acinetobacter baumannii.Journal of clinical microbiology · 2021Article
- Detection of Colistin Resistance inFrontiers in microbiology · 2021Article
- Evaluation of rapid polymyxin Nordmann Poirel test for detection of polymyxin resistance in clinical isolates of Enterobacteriaceae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Polymyxins are becoming an added value for treating infections due to multidrug-resistant Pseudomonas aeruginosa. Therefore, the Rapid Polymyxin/Pseudomonas NP test was developed for the identification of polymyxin resistance in P. aeruginosa isolates. This test detects the bacterial growth in a medium containing a defined concentration of colistin. Formation of basic metabolites is visually detected by yellow to purple/violet color change of the bromocresol purple pH indicator. The test performance was evaluated by using 50 colistin-resistant and colistin-susceptible P. aeruginosa isolates, among which 10 were colistin resistant. The sensitivity and specificity of the test were found to be 100% (CI95 65.5-100%) and 95% (CI95 81.8-99.1%), respectively, by comparison with broth microdilution as the reference method. The Rapid Polymyxin/Pseudomonas NP test is easy to perform, specific and sensitive, allowing rapid visual observation of results without the requirement any special reading equipment, and results are obtained in 3 h.
Indexed as
Identifiers
32318967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.